- GIAn tapahtumat
- Näkemyksiä ja analyysejä
- GIA yrityksenä
- Ura GIAssa
Get a snapshot of the top industry news from the Asia Pacific by email every two weeks. Subscriptions available here.
Source: The Wall Street Journal, 19 February 2012
GE Healthcare, announced today that it is to begin offering Fast Trak training in a state-of-the-art facility at the School of Life Sciences and Chemical Technology, Ngee Ann Polytechnic, Singapore. GE Healthcare's Fast Trak Training and Education Courses provide hands-on practical training in the latest technologies and strategies for bioprocessing, and are specifically designed to help biopharmaceutical manufacturers bring their product to market faster.
The scheme is unique in the life sciences sector in that it offers training that covers the whole of the downstream bioprocessing workflow. GE Healthcare currently has Fast Trak Training Centres in China, Germany, India, Japan and the US, each equipped with the latest technologies for bioprocessing, in an environment that closely replicates the industrial setting. The Singapore centre will provide easier access in the established markets of Australia and New Zealand, whilst also serving the rapidly growing markets of South East Asia, including Malaysia, Thailand and South Korea.
Source: SME News, 18 February 2012
Global research-based pharmaceutical company, Pfizer, is looking for partnerships pharmaceutical majors in India in treating cancer patients. The company draws plans for the heavy investment into the oncology research.
Oncology has been identified as the therapeutic segment for research by the company. In the emerging markets such as China and India, cancer is one of the key causes of premature deaths. Of late, the company has received the approval for Xalkori, a lung cancer drug that is expected to help the New York-based company to offset $11 billion in revenue at risk to generic copies of the best-selling Lipitor cholesterol pill.
Source: Channel News Asia, 16 February 2012
Counterfeit versions of the cancer-fighting drug Avastin have been discovered in circulation in the United States, public health officials and the pharmaceutical company Roche warned on Wednesday. Genentech said the suspect batches differ from the official product, which is certified by the FDA.
Genuine Avastin boxes are normally marked with six digit serial numbers and have no letters, stated the company. Avastin is among Roche's top-selling drugs with sales of 5.3 billion Swiss francs ($5.8 billion, 4.4 billion euros) in 2011.Last year, the FDA revoked the authorisation of Avastin for breast cancer treatment, saying its effectiveness was not proven, but allowed it to remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer.
Visit our Pharmaceuticals & Healthcare practice